Qiagen N.V. Stock Xetra

Equities

QIA

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Xetra 11:35:28 2024-05-02 am EDT After market 12:48:44 pm
39.58 EUR +1.29% Intraday chart for Qiagen N.V. 39.75 +0.41%
Sales 2024 * 2.01B 1.87B Sales 2025 * 2.14B 2B Capitalization 9.5B 8.86B
Net income 2024 * 407M 380M Net income 2025 * 450M 420M EV / Sales 2024 * 4.91 x
Net Debt 2024 * 366M 342M Net cash position 2025 * 116M 108M EV / Sales 2025 * 4.39 x
P/E ratio 2024 *
23.5 x
P/E ratio 2025 *
21.1 x
Employees 5,900
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.45%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.43%
1 week+1.68%
Current month-1.40%
1 month-1.40%
3 months-6.56%
6 months+10.29%
Current year-3.79%
More quotes
1 week
37.85
Extreme 37.845
39.57
1 month
36.59
Extreme 36.585
39.76
Current year
36.59
Extreme 36.585
43.40
1 year
33.75
Extreme 33.7526
44.81
3 years
33.75
Extreme 33.7526
53.15
5 years
23.24
Extreme 23.2371
53.15
10 years
16.63
Extreme 16.6314
53.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 15-01-31
Founder 69 96-04-28
Director of Finance/CFO 56 98-12-31
Members of the board TitleAgeSince
Director/Board Member 74 11-05-31
Founder 69 96-04-28
Chairman 66 13-06-25
More insiders
Date Price Change Volume
24-05-02 39.58 +1.29% 993 060
24-04-30 39.08 -0.17% 977,052
24-04-29 39.14 +0.99% 753,805
24-04-26 38.76 +2.16% 834,392
24-04-25 37.94 -1.65% 1,131,178

Delayed Quote Xetra, April 30, 2024 at 11:35 am EDT

More quotes
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
42.81 USD
Average target price
50.18 USD
Spread / Average Target
+17.21%
Consensus